UPCC 08422 A Phase 1b/2 Open-Label Safety and Efficacy Study of Epcoritamab (GEN3013; DuoBody -CD3 X CD20) in Relapsed/Refractory Chronic Lymphocytic Leukemia and Richters Syndrome

Age
99 years or below
Gender
All
Location
1

Brief description of study

Please refer to Protocol Section 3 (Objectives and Endpoints). Please refer to Protocol Section 3 (Objectives and Endpoints). Please refer to Protocol Section 3 (Objectives and Endpoints).

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Medical Research
  • Age: 99 years or below
  • Gender: All
Updated on 14 Jun 2023. Study ID: 851383
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu For Cancer trials contact Penn Medicine's Cancer Trial Navigator at: PMCancerResearch@pennmedicine.upenn.edu or 215-349-8245

Study is selecting its participants from a population, or group of people, decided on by the researchers in advance.

Contact Office of Clinical Research